<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.

Sinn, Marianne; Sinn, Bruno V; Treue, Denise; Keilholz, Ulrich; Damm, Frederik; Schmuck, Rosa; Lohneis, Philipp; Klauschen, Frederick; Striefler, Jana K; Bahra, Marcus; Bläker, Hendrik; Bischoff, Sven; Pelzer, Uwe; Oettle, Helmut; Riess, Hanno; Budczies, Jan; Denkert, Carsten

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.

Sinn, Marianne; Sinn, Bruno V; Treue, Denise; Keilholz, Ulrich; Damm, Frederik; Schmuck, Rosa; Lohneis, Philipp; Klauschen, Frederick; Striefler, Jana K; Bahra, Marcus; Bläker, Hendrik; Bischoff, Sven; Pelzer, Uwe; Oettle, Helmut; Riess, Hanno; Budczies, Jan; Denkert, Carsten.

Afiliação

Sinn M; Department of Medical Oncology and Haematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. ma.sinn@uke.de.
Sinn BV; University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and BMT, Hamburg, Germany.
Treue D; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Keilholz U; Berlin Institute of Health (BIH), Berlin, Germany.
Damm F; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Schmuck R; Central Biomaterial Bank Charité, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Lohneis P; Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Klauschen F; Department of Medical Oncology and Haematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Striefler JK; Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Bahra M; German Cancer Consortium (DKTK), Partner site Berlin, Germany.
Bläker H; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Bischoff S; Institute of Pathology, University Hospital Cologne, Cologne, Germany.
Pelzer U; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Oettle H; German Cancer Consortium (DKTK), Partner site Berlin, Germany.
Riess H; Department of Medical Oncology and Haematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Budczies J; Department of General, Visceral and Transplantation Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Denkert C; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Clin Cancer Res ; 26(14): 3732-3739, 2020 07 15.

Article em En | MEDLINE | ID: mdl-32234756

Assuntos

Carcinoma Ductal Pancreático/terapia; Desoxicitidina/análogos & derivados; Resistencia a Medicamentos Antineoplásicos/genética; Recidiva Local de Neoplasia/epidemiologia; Neoplasias Pancreáticas/terapia; Proteína Supressora de Tumor p53/genética; Adulto; Idoso; Idoso de 80 Anos ou mais; Carcinoma Ductal Pancreático/genética; Carcinoma Ductal Pancreático/mortalidade; Carcinoma Ductal Pancreático/patologia; Quimioterapia Adjuvante/métodos; Ensaios Clínicos Fase III como Assunto; Análise Mutacional de DNA; Desoxicitidina/farmacologia; Desoxicitidina/uso terapêutico; Intervalo Livre de Doença; Feminino; Sequenciamento de Nucleotídeos em Larga Escala; Humanos; Masculino; Pessoa de Meia-Idade; Mutação; Recidiva Local de Neoplasia/genética; Pancreatectomia; Neoplasias Pancreáticas/genética; Neoplasias Pancreáticas/mortalidade; Neoplasias Pancreáticas/patologia; Estudos Prospectivos; Ensaios Clínicos Controlados Aleatórios como Assunto; Gencitabina

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Proteína Supressora de Tumor p53 / Resistencia a Medicamentos Antineoplásicos / Carcinoma Ductal Pancreático / Desoxicitidina / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google